Traws Pharma experienced a significant increase in revenue to $2.7 million in Q2 2025, up from $57 thousand in Q2 2024, primarily due to the recognition of deferred revenue from a terminated licensing agreement. The company also dramatically reduced its net loss to $0.9 million, compared to a $123.1 million net loss in the prior year, which included a large one-time charge. Operating expenses decreased, and the company ended the quarter with $13.1 million in cash and cash equivalents.

Traws Pharma reported a net income of $21.5 million for Q1 2025, a significant improvement from a net loss in the prior year, primarily driven by a change in the fair value of warrant liability. Revenue remained stable, and the company continues to advance its antiviral programs.

Traws Pharma reported a net loss of $166.5 million for the full year 2024, driven by acquired in-process research and development expense and warrant expense. The company ended the year with $21.3 million in cash and cash equivalents, stating it has sufficient cash runway into Q1 2026. Key developments include positive data for tivoxavir marboxil in bird flu models and completion of Phase 1 studies, as well as positive data for ratutrelvir in COVID-19.

Traws Pharma reported a net loss of $8.5 million for the third quarter ended September 30, 2024. The company's cash, cash equivalents, and short-term investments were approximately $5.4 million as of September 30, 2024. The company is advancing its antiviral programs and expects to commence Phase 2 studies in 2025.

Onconova Therapeutics reported its Q2 2024 earnings, highlighting progress in clinical trials for ON 123300 and narazaciclib, and discussed financial results, including R&D expenses and cash reserves.

Traws Pharma reported first quarter 2024 financial results, including revenue of $56,000 and a net loss of $5.0 million, or $0.24 per share. The company's cash and cash equivalents were $16.4 million as of March 31, 2024, and they completed the acquisition of Trawsfynydd and a concurrent $14 million private placement financing.

Onconova Therapeutics reported its third quarter 2023 financial results, highlighting progress with narazaciclib and rigosertib, and provided updates on partnering opportunities and key personnel appointments. The company's cash and cash equivalents were reported as $25.2 million.

Onconova Therapeutics reported a net loss of $4.3 million, or $0.20 per share, for the second quarter of 2023. As of June 30, 2023, cash and cash equivalents were $29.7 million, expected to fund operations into the second quarter of 2024.

Onconova Therapeutics reported its Q3 2022 financial results, highlighting the upcoming Phase 1/2a trial of narazaciclib combined with letrozole in recurrent metastatic low-grade endometrioid endometrial cancer (LGEEC). The company's cash and cash equivalents are expected to fund operations into 2024.

Onconova Therapeutics reported a net loss of $4.0 million for the second quarter of 2022, with cash and cash equivalents totaling $46.5 million as of June 30, 2022. The company believes its cash will be sufficient to fund operations for at least eighteen months.

Onconova Therapeutics reported its full-year 2021 financial results, with cash and cash equivalents at $55.1 million. The company is progressing with its clinical trials, particularly the Phase 1 program for narazaciclib and investigator-sponsored studies for rigosertib.

Onconova Therapeutics reported a net loss of $3.5 million, or $0.22 per share, for the third quarter of 2021. Cash and cash equivalents were $59.4 million as of September 30, 2021.

Onconova Therapeutics reported a net loss of $4.2 million, or $0.27 per share, for the second quarter of 2021. As of June 30, 2021, cash and cash equivalents were $43.7 million.

Onconova Therapeutics reported its full year 2020 financial results, with a net loss of $25.2 million and cash and cash equivalents of $19.0 million as of December 31, 2020. The company is advancing its lead product ON 123300 into clinical trials and supporting investigator-initiated studies with oral rigosertib.